OC
ROSG

Oppenheimer & Co’s Rosetta Genomics Ltd. ROSG Stock Holding History

Oppenheimer & Co’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,750
Closed -$131K – 1509
2013
Q4 		$131K Hold
3,750
– – ﹤0.01% 1283
2013
Q3 		$143K Hold
3,750
– – 0.01% 1213
2013
Q2 		$153K Buy
+3,750
New +$167K 0.01% 1151

Other funds holding ROSG

BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Oppenheimer & Co's ROSG Position: Q1 2014 in Review

Oppenheimer & Co sold out of Rosetta Genomics Ltd. (ROSG) in Q1 2014, closing a stake of 3,750 shares — an estimated $131K sold.

Oppenheimer & Co first reported a position in ROSG in Q2 2013 and held it in 3 quarters. The position peaked at $153K in Q2 2013. 18 funds tracked by Wall St. Rank hold ROSG as of Q1 2014.

  • Oppenheimer & Co reported no remaining Rosetta Genomics Ltd. position as of Q1 2014 after selling out during the quarter.
  • Oppenheimer & Co sold 3,750 Rosetta Genomics Ltd. shares in Q1 2014, an estimated $131K.
  • Oppenheimer & Co first reported a position in Rosetta Genomics Ltd. in Q2 2013 and held it in 3 quarters.
  • Oppenheimer & Co's Rosetta Genomics Ltd. position peaked at $153K in Q2 2013.
  • 18 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q1 2014.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.